Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Golimumab meets Phase III endpoints

Johnson & Johnson (JNJ) said golimumab ( CNTO 148) met the primary endpoint

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE